Episode 550: SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status

Dr. Ebell and Dr. Wilkes discuss the POEM titled ' SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status '

Om Podcasten

Each week, Dr. Mark Ebell, POEMs Editor, joins Dr. Michael Wilkes, NPR correspondent and Vice-Dean of the UC-Davis Medical School, for a five minute discussion about an important recent medical study reviewed by the POEMs editors. POEMs provide synopsised reviews of studies that could affect a clinician's practice, and the discussion in this podcast provides additional depth and insight into the issue covered by the POEMs synopsis. More about POEMs and it's companion point-of-care search tool, Essential Evidence Plus, at www.essentialevidenceplus.com.